US-based drugs company Concert Pharmaceuticals has developed the new twice-a-daily pill and says that its initial trial has been promising.
Concert Pharmaceuticals has developed the new twice-a-daily pill and says that starting trial results have been promising. Four in 10 patients suffering from alopecia areata were able to regrow nearly a full head of hair within six months.
‘Trials of the first drug to treat alopecia areata showed strong results, with 30% to 40% of participants able to regrow nearly all of their hair.’
Read More..
Unfortunately, the scientist behind the drug says it can’t be used by the millions of men worldwide who lose their hair as the age.Read More..
The drug targets a more specific cause called alopecia areata. This is when the body attacks its own hair follicles.
Regrowth of Hair: A Myth or a Reality?
There are around 100,000 sufferers of alopecia areata in the UK and 6.8 million in the US. In some cases, it can cause a person to lose all their hair in a matter of weeks.According to the company, the Phase 3 trial consisted of a randomized, double-blind, placebo-controlled clinical trial in 706 adult patients aged between 18 and 65 with moderate to severe alopecia areata at sites in the U.S.
They were split into three groups, which were given a placebo, an 8 mg twice-daily pill or a 12 mg twice-daily dose. The 8 mg and 12 mg groups saw statistically significantly more regrowth than the placebo group, researchers said.
"Today marks an important milestone in advancing new treatments for alopecia areata, and I’m so happy to see such positive results from the first Phase 3 trial with CTP-543," said Brett King, MD of Yale University School of Medicine and clinical investigator.
Advertisement
Advertisement